Project Details
Description
A Phase 1/2 Study of CNDO-109-Activated Allogeneic Natural Killer Cells in Patients with High Risk Acute Myeloid Leukemia in First Complete Remission (CR1)
| Status | Finished |
|---|---|
| Effective start/end date | 1/1/12 → 8/14/19 |
Funding
- FORTRESS BIOTECH, INC.
Fingerprint
Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.